Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Question-and-Answer SessionAbsolutely. All right. So maybe, Vipin, you can start with some elevated pitch and then to see what's the state of the union for Altimmune today?Vipin GargPresident, CEO & Director Yes. So we are developing -- as you know, we are developing a glucagon GLP-1 dual receptor agonist for MASH, for liver diseases, MASH, AUD and ALD, it's a rationally designed molecule with 1:1 ratio of GLP-1 and glucagon. And we think that's very important really in order to drive the glucagon function, ...